Search results
Results From The WOW.Com Content Network
Imfinzi clocked $4.24 billion in sales in 2023, and is a blockbuster medicine in AstraZeneca's key oncology portfolio, which makes up more than 20% of its total revenues.
June 25, 2024 at 3:54 AM. (Reuters) -AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type ...
Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
Rank Drug Main indication Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2] [3] [4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
Amgen Inc. Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5] The name "AMGen" is a portmanteau of the ...
May 17, 2024 at 5:40 PM. By Blake Brittain. (Reuters) - AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung ...
The clinical trial data was strong, and the drug received a solid 8-2 recommendation from the FDA advisory. The Food and Drug Administration approval of Pfizer's (NYS: PFE) rheumatoid arthritis ...